A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells. The four main aims of the clinical trial are to find out: 1. The best dose of UCB4594 that can be given safely to participants in the trial. 2. What the side effects of UCB4594 are and how they

Trial Details

NCT ID
NCT06380816
Phase
PHASE1 / PHASE2
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • UCB4594
Locations (sample)
  • London, United Kingdom|51.50853,-0.12574
  • Manchester, United Kingdom|53.48095,-2.23743
  • Newcastle upon Tyne, United Kingdom|54.97328,-1.61396
  • Southampton, United Kingdom|50.90395,-1.40428

Key Eligibility Criteria

  • Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product (IMP) administration and follow-up
  • Participant population: Histologically or cytologically proven advanced solid tumours (as specified below), refractory to conventional treatment, o…
  • Measurable disease, according to RECIST v1.1
  • Life expectancy of at least 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →